| 研究課題/領域番号 |
23K26797
|
|---|
| 補助金の研究課題番号 |
23H02104 (2023)
|
|---|
| 研究種目 |
基盤研究(B)
|
| 配分区分 | 基金 (2024)
補助金 (2023) |
|---|
| 応募区分 | 一般 |
|---|
| 審査区分 |
小区分37030:ケミカルバイオロジー関連
|
|---|
| 研究機関 | 富山大学 |
|---|
研究代表者 |
Suresh Awale 富山大学, 学術研究部薬学・和漢系, 准教授 (00377243)
|
|---|
| 研究分担者 |
藤井 努 富山大学, 学術研究部医学系, 教授 (60566967)
|
|---|
| 研究期間 (年度) |
2023-04-01 – 2028-03-31
|
| 研究課題ステータス |
交付 (2024年度)
|
| 配分額 *注記 |
18,590千円 (直接経費: 14,300千円、間接経費: 4,290千円)
2027年度: 3,770千円 (直接経費: 2,900千円、間接経費: 870千円)
2026年度: 3,640千円 (直接経費: 2,800千円、間接経費: 840千円)
2025年度: 3,640千円 (直接経費: 2,800千円、間接経費: 840千円)
2024年度: 3,510千円 (直接経費: 2,700千円、間接経費: 810千円)
2023年度: 4,030千円 (直接経費: 3,100千円、間接経費: 930千円)
|
|---|
| キーワード | Pancreatic cancer / antiausterity / napthylisoquinolines / antitumor agents / in vivo / pancreatic cancer / chemical biology / Pancreatic canecer / anti tumor agents |
|---|
| 研究開始時の研究の概要 |
This project aimed to investigate naphthylisoquinoline alkaloids as new anti-tumor chemotherapeutic agents and provide strong preclinical evidence for drug development against pancreatic cancer through in vivo xenograft tests.
|
| 研究実績の概要 |
We investigated naphthylisoquinoline alkaloids as a potential new chemotherapeutic agent against pancreatic cancer. In 2023, we screened over 200 naphthylisoquinoline alkaloids against MIA PaCa-2 pancreatic cancer cell line and identified promising candidates. Study on structure-activity relationship to guide future development has been achieved. We've also explored the molecular mechanisms of selected compounds, which could lead to a deeper understanding of their anti-cancer effects. In addition, we also discovered novel naphthoquinones as potent antiausterity agents against human PANC-1 pancreatic cancer cells and published the results. Our findings hold promise for the development of novel, targeted treatments for this aggressive disease.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We've screened a vast library of NIQs, and identified several potent candidates with selective cytotoxicity against pancreatic cancer cells in nutrient-deprived conditions at nanomolar concentration range. We're now investigating the molecular mechanisms of these promising compounds.
|
| 今後の研究の推進方策 |
We'll extensively study the effects of our active NIQ compounds on cancer cell morphology, migration, colony formation, and chemotaxis. We'll also investigate their ability to block survival pathways within the pancreatic tumor microenvironment, aiming to enhance cancer cell death. Finally, we'll evaluate the efficacy of selected NIQs against orthotopic MIA PaCa-2 tumors, both as single agents and in combination with gemcitabine (GEM).
|
